Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2427-2436

  Theander, Elke ^a   Jonsson, Roland ^b   Sjöström, Bitte ^a,c   Brokstad, Karl ^b   Olsson, Peter ^a   Henriksson, Gunnel ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; SYNDROME; ADOLESCENT; ADULT; AGED; BAYES THEOREM; CASE CONTROL STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; REGISTER; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME; SWEDEN; TIME; VERY ELDERLY; YOUNG ADULT;

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; RHEUMATOID FACTOR; SS-A ANTIBODIES; SS-B ANTIBODIES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; BAYES THEOREM; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGISTRIES; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; SJOGREN'S SYNDROME; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 84940118840     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39214     Document Type: Article

References (33)

1. Jonsson R, Bolstad AI, Brokstad KA, Brun JG., Sjögren's syndrome: a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci 2007; 1108: 433-47.
2. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
3. Goransson LG, Haldorsen K, Brun JG, Harboe E, Jonsson MV, Skarstein K, et al., The point prevalence of clinically relevant primary Sjögren's syndrome in two Norwegian counties. Scand J Rheumatol 2011; 40: 221-4.
4. Kvarnstrom M, Ottosson V, Nordmark B, Wahren-Herlenius M., Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 2015; 44: 135-42.
5. Maldini C, Seror R, Fain O, Dhote R, Amoura Z, De Bandt M, et al., Epidemiology of primary Sjögren's syndrome in a French multiracial/multiethnic area [published erratum appears in Arthritis Care Res (Hoboken) 2014;66:794]. Arthritis Care Res (Hoboken) 2014; 66: 454-63.
6. Tozzoli R, Sorrentino MC, Bizzaro N., Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple autoimmune syndromes and overlap syndromes): a challenge for the autoimmunologist. Immunol Res 2013; 56: 425-31.
7. Martin DN, Mikhail IS, Landgren O., Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009; 50: 541-50.
8. Wahren-Herlenius M, Dorner T., Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-31.
9. Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, et al., The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases-2008. Isr Med Assoc J 2008; 10: 13-9.
10. Jonsson R, Theander E, Sjostrom B, Brokstad K, Henriksson G., Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 2013; 310: 1854-5.
11. Brucato A, Franceschini F, Buyon JP., Neonatal lupus: long-term outcomes of mothers and children and recurrence rate. Clin Exp Rheumatol 1997; 15: 467-73.
12. Julkunen H, Eronen M., Long-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001; 44: 647-52.
13. Isenberg DA, Hammond L, Fisher C, Griffiths M, Stewart J, Bottazzo GF., Predictive value of SS-B precipitating antibodies in Sjögren's syndrome. Br Med J (Clin Res Ed) 1982; 284: 1738-40.
14. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT., Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
15. Pukkala E, Andersen A, Berglund G, Gislefoss R, Gudnason V, Hallmans G, et al., Nordic biological specimen banks as basis for studies of cancer causes and control-more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol 2007; 46: 286-307.
16. Altman D, Bland JM., Diagnostic tests 2: predictive values. BMJ 1994; 309: 102.
17. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al., Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
18. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S,. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011; 13: R30.
19. Jorgensen KT, Wiik A, Pedersen M, Hedegaard CJ, Vestergaard BF, Gislefoss RE, et al., Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008; 67: 860-6.
20. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al., Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-33.
21. Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al., Young onset of primary Sjögren's syndrome: clinical and immunological characteristics. Lupus 1998; 7: 202-6.
22. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al., Primary Sjögren's syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87: 210-9.
23. Haga HJ, Jonsson R., The influence of age on disease manifestations and serological characteristics in primary Sjögren's syndrome. Scand J Rheumatol 1999; 28: 227-32.
24. Tishler M, Yaron I, Shirazi I, Yaron M., Clinical and immunological characteristics of elderly onset Sjögren's syndrome: a comparison with younger onset disease. J Rheumatol 2001; 28: 795-7.
25. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, et al., In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 2003; 48: 2240-5.
26. Bolstad AI, Wassmuth R, Haga HJ, Jonsson R., HLA markers and clinical characteristics in Caucasians with primary Sjögren's syndrome. J Rheumatol 2001; 28: 1554-62.
27. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al., Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 2013; 45: 1284-92.
28. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al., Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-8.
29. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al., Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013; 15: R172.
30. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al., Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740-50.
31. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al., Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64: 958-60.
32. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al., Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310-7.
33. Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E, et al., EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.